Biomea Fusion Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity
Reuters
Nov 05, 2025
<a href="https://laohu8.com/S/BMEA">Biomea Fusion</a> Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity
Biomea Fusion Inc. has announced the presentation of preclinical data for its investigational oral small molecule GLP-1 receptor agonist, BMF-650, and combination data for its covalent menin inhibitor candidate, icovamenib, with semaglutide at ObesityWeek® 2025. The preclinical studies demonstrated that BMF-650 produced potent weight loss and strong glycemic control in obese cynomolgus monkeys, with improvements in insulin sensitivity and preservation of lean mass. Additionally, in a rodent model of type 2 diabetes, the combination of icovamenib and low dose semaglutide showed enhanced glycemic control and body weight reduction compared to semaglutide alone. A Phase I study of BMF-650 in healthy obese patients is currently enrolling, with data expected in the first half of 2026. Biomea Fusion plans to begin clinical evaluation of icovamenib in patients with type 2 diabetes on GLP-1 based treatment in the fourth quarter of 2025, with first patient dosing expected in the first quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568770-en) on November 05, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.